Janssen Pharmaceutica Nv

3-dimensional Pharmaceuticals, Inc.

Ehab Khalil

Jeremy Mark Travins

Kristi A Leonard

Heather Rae Hufnagel

Maxwell David Cummings

Shelley K Ballentine

Farah Ali

Nalin L Subasinghe

Tianbao Lu

Mark James Wall

Sanath K Meegalla

Jinsheng Chen

Thomas P Markotan

Dana L Johnson

Robert W Tuman

Hui Huang

Michael Peter Winters

Richard Scott Alexander

Wenxi Pan

Jan L Sechler

Richard William Connors

Robert A Galemmo

Anna C Maroney

Joan Gushue

Joan M Gushue

Roger Francis Bone

Kenneth J Wilson

M Jonathan Rudolph

Jonathan Rudolph

Kenneth T Wilson

The invention is directed to triazolopyridazine compounds of Formula I: where R, R, R, R, R, and A are as defined herein, the use of such compounds as protein tyrosine kinase modulators, particularly inhibitors of c-Met, and the use of such compounds to reduce or inhibit kinase activity of c-Met in a cell or a subject, and modulate c-Met expression in a cell or subject, and the use of such compounds for preventing or treating in a subject a cell proliferative disorder and/or disorders related to c-Met. The present invention is further directed to pharmaceutical compositions comprising the compounds of the present invention and to methods for treating conditions such as cancers and other cell proliferative disorders.

Triazolopyridazine compounds

Triazolopyridazines as kinase modulators

Disclosed are compounds for treating the symptoms of an acute or chronic disorder mediated by the classical pathway of the complement cascade. The compounds are of Formula I or a solvate, hydrate, pharmaceutically acceptable salt, or prodrug thereof; wherein R, R, and Rare as defined in the specification, as are A Z, Q, Rand R.

Thiophene sulfoximines, compositions thereof, and methods of treating complement-mediated diseases and conditions

The present invention is directed to conjugated complement cascade inhibitors, and a method of treating a patient using a conjugated complement cascade inhibitor.

Conjugated complement cascade inhibitors

Disclosed are compounds for treating the symptoms of an acute or chronic disorder mediated by the classical pathway of the complement cascade. The compounds are of Formula I or a solvate, hydrate, pharmaceutically acceptable salt, or prodrug thereof; wherein R, R, and Rare defined in the specification, as are A Z, Q, Rand R.

Disclosed is a method for treating the symptoms of an acute or chronic disorder mediated by the classical pathway of the complement cascade, comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound of Formula (I) or a solvate, hydrate or pharmaceutically acceptable salt thereof; wherein R, R, R, Rand Rare defined in the specification, Z is SO or SO, and Ar is an aromatic or heteroaromatic group as defined herein. 

Thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions

Disclosed is a method for treating the symptoms of an acute or chronic disorder mediated by the classical pathway of the complement cascade, comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound of Formula I or a solvate, hydrate or pharmaceutically acceptable salt thereof; wherein R, R, R, Rand Rare defined in the specification, Z is SO or SO, and Ar is an aromatic or heteroaromatic group as defined herein.

Growing community of inventors

West Chester, PA, United States of America

Ehab Khalil